Advertisement
U.S. markets open in 5 hours 57 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
959.92-4.55 (-0.47%)
At close: 04:00PM EDT
960.11 +0.19 (+0.02%)
After hours: 04:34PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close964.47
Open970.00
Bid965.00 x 1000
Ask966.02 x 1000
Day's Range959.49 - 970.71
52 Week Range684.81 - 998.33
Volume360,091
Avg. Volume530,555
Market Cap105.363B
Beta (5Y Monthly)0.11
PE Ratio (TTM)27.63
EPS (TTM)34.74
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,036.19
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
5% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for REGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Regeneron Pharmaceuticals, Inc.
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    20 hours agoArgus Research
View more
  • Reuters

    US appeals court revives Regeneron's antitrust lawsuit against Novartis

    A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness. The 2nd U.S. Circuit Court of Appeals in Manhattan said a lower court judge erred in dismissing the case, in part for having applied an improper legal standard to Regeneron's claims. Regeneron in a statement said it was "encouraged by the 2nd Circuit’s decision" and looked forward to "further advancing our position in future proceedings."

  • Insider Monkey

    11 Oversold Biotech Stocks To Buy Right Now

    In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip our detailed analysis of the biotech sector, you can go directly to see the 5 Oversold Biotech Stocks To Buy Right Now. Dealmaking in Biotech Healthcare has been performing well so far in 2024, and […]

  • Simply Wall St.

    Regeneron Pharmaceuticals Insiders Sold US$26m Of Shares Suggesting Hesitancy

    Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...